



## PharmaMar Group reports results for the first quarter of 2019

- Sales of Yondelis® in the first quarter were €17.1 million.
- Operating expenses decreased for almost all items.
- Operations in the consumer chemicals segment have been classified as discontinued operations due to Zelnova-Zeltia's process of sale.

Madrid, April 26<sup>th</sup>, 2019.- PharmaMar Group (MSE: PHM) reported total sales of €18.4 million in the first three months of 2019, compared to €19.7 million in the same period of 2018. Sales of Yondelis® accounted for €17.1 million, compared to €18.4 million in March 2018. As in previous quarters, price erosion was one of the main factors behind the difference in Yondelis® sales figures between quarters.

During the first three months of 2019, royalty income of €0.9 million was recorded, compared to €1.4 million during the first three months of the previous year. In relation to license revenues, no license revenues were recorded in the first quarter of 2019, which explains the difference in total revenues in this period (€19.4 million, compared to €27.8 million in 2018). After the closing date, a license agreement has been signed with Luye Pharma Group Ltd. for the marketing of Zepsyre® (lurbinedin) in China, with an initial payment of US\$5 million as part of the agreement, which will be registered in the second quarter of this year.

Sales in the consumer chemicals sector, which grew by 16.6% in the first quarter, are not included in the Group's total revenues as the companies forming part of the sector were classified as available for sale/interrupted operations, both in March 2019 and in the same period in 2018.

As a result, at the end of the first quarter of 2019, the group's EBITDA was €-7.1 million compared to €-2.6 million in March 2018.

At March 31, 2018, the Group's profit from continuing operations was €-10.4 million compared to €-2.5 million in the first quarter of 2018.



#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com)

#### **Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127  
Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Phone: +34 918466000

#### **Investor Relations:**

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)  
Phone: +34 914444500



Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)